Eli Lilly and Regeneron are among seven companies tapped by the U.S. Food and Drug Administration for a new PreCheck Pilot Program, according to a report shared with CNBC. The early list places two of the world’s largest drugmakers at the front of an experiment that could change how the agency prepares for reviews. The move arrives as drug pipelines swell and pressure grows to speed access while keeping safety high.
“Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC has learned.”
Why A Pre-Review Pilot Matters
The FDA has tested several tools to make reviews more efficient. Over the past decade, it expanded use of Priority Review, Breakthrough Therapy designation, and Real-Time Oncology Review. Those pathways do not change standards, but they can move work earlier in the process. A PreCheck model fits that arc. It suggests the agency plans to triage materials up front, surface gaps sooner, and reduce last-minute surprises.
For large firms like Eli Lilly and Regeneron, earlier feedback could help teams align study methods, manufacturing plans, and safety tracking before a filing. For the FDA, front-loading checks may save time later and ease staff bottlenecks. Standard drug reviews target about 10 months. Priority reviews target about six. Even small gains can affect launch timing, access, and costs.
What Selection Signals For Big Pharma
Eli Lilly and Regeneron both have high-profile pipelines. Lilly has bet on obesity and diabetes drugs, as well as Alzheimer’s. Regeneron is active in eye disease, immunology, and cancer. Being chosen suggests the FDA wants participants with steady filing volume and strong compliance records to help test the model under real pressure.
Investors will read the news as a sign that complex filings could move with fewer delays. Patient groups will look for faster, clearer answers on therapies with urgent need. Yet speed is only one goal. More predictable reviews and fewer information requests midstream can also reduce costs for trials and manufacturing scale-up.
Questions The Pilot Must Answer
- Scope: Will PreCheck cover clinical data, chemistry and manufacturing, labeling, or all of the above?
- Timing: How early will companies engage, and how long will PreCheck steps take?
- Eligibility: Will small biotechs and first-time filers gain access, or will the pilot focus on large firms first?
- Metrics: What measures—cycle times, fewer review letters, postmarket safety outcomes—will define success?
Patient advocates often worry that speed can strain safety oversight. Former regulators have argued that earlier, deeper interactions can improve safety by fixing study design flaws before they spread. The pilot will face scrutiny on both fronts.
Impact On Patients And The Market
If the pilot works, patients could see answers sooner, even when the FDA says no. Clearer, earlier feedback can redirect trials to better endpoints or patient groups. That can cut wasted time and limit exposure to ineffective doses.
For companies, time is money. Every month a major drug reaches shelves sooner can shift revenue forecasts and R&D plans. The flip side is fairness. If early slots go mostly to large firms, smaller developers may worry about access. A transparent expansion plan could ease those concerns.
How This Fits Wider FDA Trends
Congress has pushed the agency to stay nimble through laws reauthorizing user fees and modernizing trial rules. The FDA has also endorsed more use of real-world evidence in limited cases and more adaptive study designs. A PreCheck Pilot would sit alongside those efforts, not replace them. It would aim to clean up filings before the formal clock starts, much like pre-submission meetings but with tighter structure and clearer deliverables.
What To Watch Next
Key signals to track will be how the FDA describes the pilot’s scope, whether other selected companies are named, and when the first outcomes are published. Watch for whether oncology or metabolic drugs dominate early participation. Also watch for any public metrics on review time, number of review cycles, and safety issues caught early.
The early inclusion of Eli Lilly and Regeneron shows the FDA is seeking partners who can stress-test the process. The next phase will test whether earlier screening improves both speed and quality. Readers should look for concrete metrics and a plan to widen access if the model works. That will show whether PreCheck becomes a niche tool or a standard step on the path to new medicines.
